J Intern Med:新型胶原因子Endotrophin可预测动脉粥样硬化患者的心血管事件和死亡风险

2021-05-06 Nebula MedSci原创

PRO‐C6存在于动脉粥样硬化斑块中,并与患者未来的心血管事件、心血管死亡和全因死亡风险相关

动脉粥样硬化斑块破裂是急性血管事件的主要原因。Endotrophin是一种VI型胶原因子,可采用生物标记物PRO-C6检测,或可为检测需要加强二级预防的心血管疾病患者提供有价值的信息。

本研究旨在通过检测动脉粥样硬化患者动脉粥样硬化斑块中的内啡肽和循环中的PRO-C6水平,以确定该生物标志物的在动脉粥样硬化患者中的预测价值。

颈动脉斑块PRO-C6抗体染色

取人颈动脉斑块切片,进行PRO-C6抗体染色。检测了参加颈动脉斑块成像项目(CPIP)(发现队列,n=577)和IMI-Summit项目(验证队列,n=1378)的患者的血清PRO-C6水平。

血清PRO-C6水平与患者无事件存活率的相关性

中位随访时间为43个月。PRO-C6定位于动脉粥样硬化斑块的核心和前部。在发现队列中, PRO‐C6可独立预测患者未来的心血管事件(HR 1.089 [95%CI 1.019-1.164],P=0.01)、心血管死亡(HR 1.118 [95%CI 1.008-1.241],P=0.04)和全因死亡(HR 1.087[95%CI 1.008-1.172],P=0.03)风险

在验证队列中,验证了PRO‐C6可预测患者未来的心血管事件(OR 1.063 [95%CI 1.011-1.117],p=0.017)。

综上,在两个较大的前瞻性队列中,PRO‐C6存在于动脉粥样硬化斑块中,并与患者未来的心血管事件、心血管死亡和全因死亡风险相关,提示新型胶原因子Endotrophin可预测动脉粥样硬化患者的心血管事件和死亡风险

原始出处:

Holm Nielsen S,Edsfeldt A,Tengryd C et al. The novel collagen matrikine, endotrophin, is associated with mortality and cardiovascular events in patients with atherosclerosis. J Intern Med, 2021, https://doi.org/10.1111/joim.13253

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643740, encodeId=faab1643e404d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Dec 17 14:59:09 CST 2021, time=2021-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952181, encodeId=5e94195218119, content=<a href='/topic/show?id=daab6e74a5' target=_blank style='color:#2F92EE;'>#Endotrophin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6774, encryptionId=daab6e74a5, topicName=Endotrophin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 12 03:59:09 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944699, encodeId=08ed19446996d, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Mon May 24 07:59:09 CST 2021, time=2021-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256079, encodeId=800c12560e9f1, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611034, encodeId=d98216110347a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631274, encodeId=8c5416312e42d, content=<a href='/topic/show?id=0d2b1353679' target=_blank style='color:#2F92EE;'>#OTR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13536, encryptionId=0d2b1353679, topicName=OTR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb2621702447, createdName=jichang, createdTime=Sat May 08 07:59:09 CST 2021, time=2021-05-08, status=1, ipAttribution=)]
    2021-05-08 jichang

相关资讯

J Am Coll Cardiol:ARIC研究| NT-proBNP、血压和心血管事件的相关性

NT-proBNP)是否有助于识别不同收缩压(SBP)、舒张压(DBP)或脉压(PP)水平的心血管事件高危人群?

JAHA:急性冠脉综合征患者血浆ω-3脂肪酸与心血管事件风险的关系

在急性冠脉综合征患者中,血浆长链ω3-PUFA与心源性猝死的降低几率成负相关,而与传统的危险因素和血脂无关。

JAHA:空气颗粒物污染与卒中或急性心肌梗塞成人心血管事件风险的关系

伴有CVD病史的成年人易受PM2.5暴露的影响,尤其是对CVD死亡率的影响。在PM2.5<12 µg/m3的暴露水平下观察到风险增加,表明当前的PM2.5法规水平可能对该易感人群没有保护作用。

IBD:炎症性肠病的疾病活动与动脉血管疾病的发病率增加有关

尽管炎症性肠病(IBD)主要影响患者的肠道,但是作为一种全身性疾病也会影响身体的其他器官,包括静脉血栓栓塞症(VTE),葡萄膜炎和脓皮病坏疽等。

JAHA:高血压患者诊室血压与心血管事件

在所有高血压患者中,BP水平均与MACE风险显著相关。但是,在接受降压治疗的BP<120/70 mmHg的患者中,并无额外的MACE益处。

Circulation:心肌梗死后一年内复发心血管事件的男女差异!

在美国,复发冠心病(CHD)事件的发生率已经下降。但很少有研究评估这种下降是否存在男女差异。